Daiichi Sankyo and MSD Expand Collaboration to Co-Develop and Co-Commercialize DLL3 T-Cell Engager MK-6070

Agreement builds on and complements Daiichi Sankyo and Merck’s shared commitment to develop novel medicines for patients with cancer Daiichi Sanky...

August 07, 2024 | Wednesday | News
Fifty 1 Labs and All-In-Extracts Announce Joint Venture for Innovative Testosterone-Boosting Supplement

Fifty 1 Labs, Inc. , a holding company that operates in the sports supplement, fitness equipment, and health and wellness industries, and All-In-Extracts...

August 06, 2024 | Tuesday | News
Molecure and Avicenna Biosciences Announce Strategic Collaboration to Develop Novel Cancer Therapies Targeting USP7

Molecure S.A. (‘Molecure’, SWE Ticker: MOC) and Avicenna Biosciences, Inc. announced today that they have entered into a strategic research c...

August 01, 2024 | Thursday | News
FDA Grants Priority Review to Vertex's Suzetrigine, Targeting January 2025 for Action Date

FDA grants priority review and assigns a Prescription Drug User Fee Act (PDUFA) target action date of January 30, 2025 – – Suzetrigine...

July 30, 2024 | Tuesday | News
Charles River Partners with Autobahn Labs to Accelerate Academic Drug Discovery and Development

Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to acceler...

July 25, 2024 | Thursday | News
Innovent Biologics Announces Phase 3 Success for Mazdutide in Treating Type 2 Diabetes

Innovent Biologics, a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of on...

July 22, 2024 | Monday | News
Teva Pharmaceuticals’ AJOVY Achieves Primary End Point in Pediatric Phase 3 Migraine Study

SPACE pediatric Phase 3 study met its primary end point for efficacy with a significantly greater reduction in Monthly Migraine Days compared to ...

July 19, 2024 | Friday | News
Shanghai Junshi Biosciences' sNDA for Toripalimab and Bevacizumab Combo for Advanced Liver Cancer Accepted by NMPA

  Shanghai Junshi Biosciences Co., a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercializati...

July 19, 2024 | Friday | News
China's NMPA Approves First and Only Subcutaneous FcRn Blocker for gMG Patients

First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China Consistent clinical benefit and safety profile of efgartigim...

July 16, 2024 | Tuesday | News
Rznomics Inc. Receives Approval for Phase 1/2a Clinical Trial of RZ-004 in Australia

Rznomics Inc., a South Korea based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, announced that it has receive...

July 15, 2024 | Monday | News
Eisai and Biogen Announce Approval of Alzheimer’s Treatment LEQEMBI® in Israel

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher...

July 12, 2024 | Friday | News
BioArctic AB’s Partner Eisai Announces Approval of Leqembi® (樂意保®) for Alzheimer’s Disease Treatment in Hong Kong

BioArctic AB  is pleased to announce that its partner, Eisai, has received approval from the Department of Health in Hong Kong for Leqembi® (bra...

July 11, 2024 | Thursday | News
Certara to Acquire Chemaxon, Expanding Biosimulation Capabilities in Drug Discovery

Certara, Inc.  a global leader in model-informed drug development, today announced it has signed a definitive agreement to acquire Chemaxon, a leadi...

July 10, 2024 | Wednesday | News
Certara to Acquire Chemaxon, Expanding Biosimulation Capabilities in Drug Discovery

Certara, Inc.  a global leader in model-informed drug development, today announced it has signed a definitive agreement to acquire Chemaxon, a leadi...

July 10, 2024 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close